Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.

Karin M KnudsonKristin C HicksSarah AlterJeffrey SchlomSofia R Gameiro

Published in: Journal for immunotherapy of cancer (2019)

We provide novel insight into the mechanism of action of N-803 plus anti-PD-L1 combination and offer preclinical proof of concept supporting clinical use of N-803 in combination with checkpoint inhibitors, including for patients non- and/or minimally responsive to either monotherapy.

Keyphrases

ejection fraction
newly diagnosed
dna damage
prognostic factors
stem cells
combination therapy
cell cycle
clinical trial
open label
study protocol